SCHEMBL10114574

SCHEMBL10114574

CC(C)(C)NC(=O)c1ccc(NC(=O)C2CCC(NS(=O)(=O)C(C)(C)C)CC2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 1/20 0.54
KMT2A Q03164 4/20 0.47
USP2 O75604 1/20 0.46
LMNA P02545 2/20 0.46
NAMPT P43490 1/20 0.45
RAB9A P51151 1/20 0.43
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
SIRT5 Q9NXA8 1/20 0.42
GLA P06280 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MAPT P10636 2/20 0.41
TSHR P16473 1/20 0.41
ENPP3 O14638 3/20 0.41
ENPP1 P22413 3/20 0.41
MEN1 O00255 2/20 0.41
ENPP2 Q13822 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14424619 1.00 NPY5R (0.54) NPY5RKMT2AUSP2LMNANAMPT
SCHEMBL13203753 0.87 L3MBTL1 (0.56) NPY5RKMT2ALMNANAMPTRAB9A
SCHEMBL10113200 0.87 L3MBTL1 (0.56) NPY5RKMT2ALMNANAMPTRAB9A
SCHEMBL14627725 0.86 NPY5R (0.53) NPY5RKMT2ALMNANAMPTRAB9A
SCHEMBL12882794 0.86 NPY5R (0.53) NPY5RKMT2ALMNANAMPTRAB9A
SCHEMBL10114965 0.86 KMT2A (0.45) NPY5RKMT2AUSP2LMNANAMPT
SCHEMBL13204420 0.86 KMT2A (0.45) NPY5RKMT2AUSP2LMNANAMPT
SCHEMBL10133217 0.85 NPY5R (0.61) NPY5RKMT2ALMNANAMPTGLA
SCHEMBL10114310 0.85 NPY5R (0.61) NPY5RKMT2ALMNANAMPTGLA
SCHEMBL14424762 0.85 LMNA (0.54) NPY5RKMT2ALMNANAMPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R NPY5R 1/4885KMT2A 2912/4885USP2 3137/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R NPY5R 1/4885KMT2A 2768/4885USP2 3680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.